NCT06438783View on ClinicalTrials.gov

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

February 28, 2026

Conditions
OsteosarcomaOther Solid Tumors
Interventions
DRUG

1200mg of TQB2928 injection+Anlotinib

TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).

DRUG

1800mg of TQB2928 injection+Anlotinib

TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.

Trial Locations (5)

100035

NOT_YET_RECRUITING

Beijing jishuitan hospital, Beijing

100044

RECRUITING

Pekjing university people's hospital, Beijing

100142

NOT_YET_RECRUITING

Beijing cancer hospital, Beijing

300181

NOT_YET_RECRUITING

Tianjin medical university cancer institute&hospital, Tianjin

410031

NOT_YET_RECRUITING

Hunan cancer hospital, Changsha

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY